Quick Answer
Celldex Therapeutics, Inc. reported Stockholders Equity of $527.17 million for the year ending 2025.
- Celldex Therapeutics, Inc. showed a decrease of -29.4% in Stockholders Equity from 2024 to 2025.
- This data is from Celldex Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2013: $319.80 million | Q1 2014: $291.85 million | Q2 2014: $265.32 million | Q3 2014: $239.37 million | Q1 2015: $375.55 million | Q2 2015: $345.88 million | Q3 2015: $318.63 million | Q1 2016: $260.03 million | Q2 2016: $234.71 million | Q3 2016: $217.09 million | Q1 2017: $247.84 million | Q2 2017: $231.46 million | Q3 2017: $219.15 million | Q1 2018: $134.09 million | Q2 2018: $128.05 million | Q3 2018: $128.14 million | Q1 2019: $112.69 million | Q2 2019: $109.63 million | Q3 2019: $101.38 million | Q1 2020: $83.70 million | Q2 2020: $238.44 million | Q3 2020: $229.98 million | Q1 2021: $194.17 million | Q2 2021: $182.28 million | Q3 2021: $436.71 million | Q1 2022: $398.10 million | Q2 2022: $365.09 million | Q3 2022: $345.42 million | Q1 2023: $302.74 million | Q2 2023: $277.54 million | Q3 2023: $246.72 million | Q1 2024: $838.61 million | Q2 2024: $813.66 million | Q3 2024: $785.91 million | Q1 2025: $702.98 million | Q2 2025: $655.41 million | Q3 2025: $598.36 million.
- Over the full 14 years of available data (2012 to 2025), Celldex Therapeutics, Inc.'s Stockholders Equity has grown by 450.4%.
- Historical annual values: Fiscal year 2025: $527.17 million | Fiscal year 2024: $747.01 million | Fiscal year 2023: $429.17 million | Fiscal year 2022: $326.20 million | Fiscal year 2021: $419.48 million | Fiscal year 2020: $209.36 million | Fiscal year 2019: $94.03 million | Fiscal year 2018: $124.06 million | Fiscal year 2017: $236.37 million | Fiscal year 2016: $265.43 million | Fiscal year 2015: $290.11 million | Fiscal year 2014: $211.66 million | Fiscal year 2013: $319.80 million | Fiscal year 2012: $95.77 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: